Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12926680 | 0.87 | F10 (0.45) | F10NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL1004839 | 0.83 | F10 (0.44) | F10NPC1RAB9ASMN1; SMN2MIF | |
| SCHEMBL1023288 | 0.81 | F10 (0.65) | F10 | |
| SCHEMBL1095841 | 0.78 | F10 (0.46) | F10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1096774 | 0.78 | F10 (0.48) | F10NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL1101328 | 0.77 | F10 (0.46) | F10NPC1RAB9ASMN1; SMN2MIF | |
| SCHEMBL1096474 | 0.77 | NPC1 (0.52) | F10NPC1RAB9A | |
| SCHEMBL1023752 | 0.77 | F10 (0.63) | F10 | |
| SCHEMBL1095884 | 0.77 | F10 (0.47) | F10NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL10313036 | 0.77 | F10 (0.45) | F10NPC1RAB9ASMN1; SMN2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015241-A1 | SUBSTITUTED HETEROCYCLES AND USE THEREOF | F2, VKORC1, HMBS | F10 104/4885NPC1 1664/4885RAB9A 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.